Ehealthcaresolutionsfeedatom

Pharma sales teams once relied heavily on face-to-face physician engagement. However, the healthcare landscape has changed dramatically. Today, many integrated delivery networks (IDNs), hospitals, and large health systems permanently restrict access to pharmaceutical representatives. As a result, the rise of the “no-see” physician is reshaping commercial strategy across the i...

As several blockbuster biologics lose exclusivity in 2026, the pharmaceutical industry is entering a new competitive era. Biosimilar manufacturers are aggressively preparing to capture market share, while originator brands are working harder to retain prescribing loyalty. This shift is transforming biosimilar drug marketing from broad awareness campaigns into precision-driven...

Many healthcare media plans look polished during strategy meetings but struggle once real-world conditions begin affecting campaign delivery. A plan may appear efficient on paper, yet unexpected compliance delays, reporting gaps, inventory shortages, and optimization slowdowns can quickly reduce performance after launch. That is why smart healthcare marketers now treat campai...

Modern medicine no longer fits neatly into one specialty at a time. A patient with obesity may also struggle with diabetes, cardiovascular disease, chronic inflammation, or sleep apnea. At the same time, new therapies increasingly address multiple conditions together instead of treating one isolated diagnosis. Because of this shift, pharma marketers are increasingly using com...

Pharma marketers often focus on the same small group of high-prescribing physicians. While that strategy can deliver quick wins, it also creates a blind spot that limits long-term growth. Many brands continue investing heavily in Decile 8–10 healthcare professionals while overlooking the physicians sitting in the middle of the prescribing curve. That “missing middle” includes...